Brokers Set Expectations for Dyadic International, Inc.’s Q2 2024 Earnings (NASDAQ:DYAI)

Dyadic International, Inc. (NASDAQ:DYAI) – Analysts at HC Wainwright issued their Q2 2024 earnings estimates for shares of Dyadic International in a research note issued to investors on Monday, July 8th. HC Wainwright analyst V. Bernardino forecasts that the biotechnology company will post earnings of ($0.06) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Dyadic International’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Dyadic International’s Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.24) EPS and FY2025 earnings at ($0.11) EPS.

Dyadic International Price Performance

Shares of DYAI opened at $1.37 on Wednesday. The company has a 50 day moving average price of $1.74 and a 200-day moving average price of $1.60. The company has a debt-to-equity ratio of 1.29, a quick ratio of 5.54 and a current ratio of 5.54. The stock has a market capitalization of $40.06 million, a PE ratio of -4.89 and a beta of 0.73. Dyadic International has a fifty-two week low of $1.19 and a fifty-two week high of $2.67.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter. The firm had revenue of $0.33 million during the quarter. Dyadic International had a negative return on equity of 116.14% and a negative net margin of 347.92%. During the same quarter in the prior year, the business posted ($0.03) earnings per share.

Institutional Investors Weigh In On Dyadic International

An institutional investor recently bought a new position in Dyadic International stock. Callan Capital LLC acquired a new stake in Dyadic International, Inc. (NASDAQ:DYAI) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 27,174 shares of the biotechnology company’s stock, valued at approximately $45,000. Callan Capital LLC owned about 0.09% of Dyadic International as of its most recent SEC filing. 27.95% of the stock is currently owned by institutional investors.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.